Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial

Published:2017-10-06 Issue:10 Volume:14 Page:e1002402
ISSN:1549-1676
Container-title:PLOS Medicine
language:en
Short-container-title:PLoS Med

Author:

Agnandji Selidji T.,Fernandes José F.,Bache Emmanuel B.,Obiang Mba Régis M.,Brosnahan Jessica S.,Kabwende Lumeka,Pitzinger Paul,Staarink Pieter,Massinga-Loembe Marguerite,Krähling Verena,Biedenkopf Nadine,Fehling Sarah Katharina,Strecker Thomas,Clark David J.,Staines Henry M.,Hooper Jay W.,Silvera Peter,Moorthy Vasee,Kieny Marie-Paule,Adegnika Akim A.,Grobusch Martin P.,Becker Stephan,Ramharter Michael,Mordmüller Benjamin,Lell Bertrand,Krishna Sanjeev^ORCID,Kremsner Peter G.,

Funder

Universitätsklinikum Tübingen in Germany

Wellcome Trust (UK)

The Bill & Melinda Gates Foundation (US)

Bundesministerium für Gesundheit (BMG, Germany)

The German Center for Infection Research (DZIF)

The Land Baden-Württemberg

Publisher

Public Library of Science (PLoS)

Subject

General Medicine

Reference31 articles.

1. World Health Organization. Ebola situation report—30 March 2016. Geneva: World Health Organization; 2016 [cited 2016 Apr 29]. Available from: http://apps.who.int/ebola/current-situation/ebola-situation-report-30-march-2016.

2. Ebola outbreak 2014–2015,2016

3. Clinical development of Ebola vaccines;S Sridhar;Ther Adv vaccines,2015

4. Ebola vaccines in clinical trial: the promising candidates;Y Wang;Hum Vaccin Immunother,2017

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon;Journal of Infection;2024-10

2. Immunogenicity and safety of ebolavirus vaccines in healthy adults: a systematic review and meta-analysis of randomized controlled trials;Expert Review of Vaccines;2023-12-22

3. Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults;Clinical Infectious Diseases;2023-11-15

4. Vaccines to prevent Ebola virus disease: current challenges and perspectives;Problems of Virology;2023-11-07

5. Ebola virus disease in children: epidemiology, pathogenesis, management, and prevention;Pediatric Research;2023-10-30